Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
NPJ Vaccines|March 8, 2024
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccineValentino Conti, Omar Rossi, Kristen A Clarkson, et al.
The Lancet. Infectious Diseases|December 3, 2013
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trialsZulfiqar A Bhutta, Maria Rosario Capeding, Ashish Bavdekar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM<sub>197</sub> conjugate vaccineFrancesca Micoli, Stefania P Bjarnarson, Melissa Arcuri, et al.
Ebiomedicine|July 25, 2017
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeOdile Launay, David J M Lewis, Alessandra Anemona, et al.
NPJ Vaccines|September 5, 2023
A next-generation GMMA-based vaccine candidate to fight shigellosisOmar Rossi, Francesco Citiulo, Carlo Giannelli, et al.
Plos Clinical Trials|April 7, 2007
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malariaElissa Malkin, Carole A Long, Anthony W Stowers, et al.
Frontiers in Immunology|June 18, 2026
Development of a GMMA-based candidate vaccine against invasive nontyphoidal <i>Salmonella</i> diseaseFrancesco Citiulo, Oliver Koeberling, Omar Rossi, et al.
Tropical Medicine & International Health : TM & IH|July 29, 2014
Typhoid fever in Fiji: a reversible plague?Corinne N Thompson, Mike Kama, Shrish Acharya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2009
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individualsPeter D Crompton, Marko Mircetic, Greta Weiss, et al.
Vaccine|October 31, 2009
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adultsIssaka Sagara, Ruth D Ellis, Alassane Dicko, et al.
Pageof 8